Addiction Medicine — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, fill rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-25.

Also called: ADM, addiction med. Multidisciplinary subspecialty fellowship, entered from almost any base residency (Addiction Medicine, ABPM); a separate Addiction Psychiatry route exists for psychiatrists (ABPN). Organ system: the brain's reward circuitry, though really the whole person, since substance use disorders touch every organ and every part of a life.

The 30-second version

Addiction medicine is the specialty built around one of the oldest problems in medicine and one of its most urgent crises: treating substance use disorders as the chronic, relapsing, treatable diseases they are. You manage opioid, alcohol, and stimulant use disorders mostly in the outpatient setting: prescribing buprenorphine and other medications, running or overseeing treatment programs, coordinating counseling, and building long relationships with patients much of the rest of medicine would rather not deal with. The day-to-day looks more like chronic-disease management than acute rescue, closer to managing diabetes than curing pneumonia. What makes it distinctive is the combination, since the schedule is unusually livable: some of the most concretely life-saving work in medicine, carried inside a system that funds it grudgingly and a culture that still stigmatizes both the field and its patients.

Quick dashboard (details and sources below)
Training after med school Base residency (3–4 yrs) + Addiction Medicine fellowship (1 yr)
Total from college start ~12 years (4 undergrad + 4 med school + 3–4 base residency + 1 fellowship)
Competitiveness Low–moderate — genuinely accessible; positions routinely go unfilled ⟳
Typical full-time pay ~$300,000–$340,000 total comp (median ~$315k) ⟳
Pay range (structure) 25th pct ~$285k · median ~$315k · 75th pct ~$340k · 90th pct ~$500k ⟳
Lifestyle Largely outpatient, minimal call, telehealth-friendly, ~42 hr/week ⟳
Burnout Variable — sourced from grief, stigma & underfunding, not hours ⟳
% women / demographics 52.8% of fellows are women (ACGME AY2024-25, n=216); no practicing-workforce table ⟳

What they actually do

Addiction medicine physicians treat substance use disorders (SUDs), including opioid, alcohol, stimulant, sedative, and tobacco, as chronic, relapsing medical conditions. The core of the job is longitudinal outpatient care: office-based treatment of opioid use disorder with buprenorphine (MAT), managing alcohol and stimulant use disorders, overseeing methadone and treatment programs, and coordinating the counseling and social supports that recovery depends on. Much of it is relationship-driven and cognitive rather than procedural. You're managing a relapsing condition over months and years, adjusting medications, holding hope, and meeting patients where they are.

The work spans settings. Beyond the outpatient clinic there are hospital-based addiction consult services (seeing admitted patients with withdrawal, endocarditis from injection use, or new diagnoses), residential and intensive-outpatient (IOP) programs, opioid treatment programs (OTPs), VA and correctional health, and a fast-growing world of telehealth. A common and flexible model is a physician who keeps practicing a base specialty, whether family medicine, IM, or EM, and runs an addiction clinic a couple of days a week.

Representative work: buprenorphine induction and maintenance · methadone/OTP oversight · naltrexone and alcohol-use-disorder pharmacotherapy · management of withdrawal (opioid, alcohol, benzodiazepine) · harm-reduction counseling (naloxone, safer-use guidance) · co-management of co-occurring psychiatric illness · inpatient addiction consults · treatment-program medical direction. The field is largely non-procedural, and its "procedure" is the medication, the plan, and the relationship.

A day in the life: Mostly clinic. You see a panel of patients you know over time: some stable on buprenorphine and doing well, some who relapsed since last visit, some brand new and ambivalent. There's counseling, medication management, and a lot of listening. If you're on a hospital consult service, you round on admitted patients with withdrawal or injection-related infections and help the primary team start treatment. Overnight call is minimal in most settings. When the day ends, you generally go home. The load you carry out the door is emotional rather than logistical.

The training path & time to completion

This is a multidisciplinary fellowship, one of the widest front doors in medicine. You do not match into addiction medicine out of med school; you finish a full base residency first and then add a one-year fellowship. Crucially, almost any base specialty qualifies.

Two distinct roads lead to nearly the same work, and the difference matters:

  • Addiction Medicine (ADM), the multidisciplinary route. Board: the American Board of Preventive Medicine (ABPM), certifying on behalf of all ABMS boards. Open to physicians from any primary specialty: internal medicine, family medicine, emergency medicine, pediatrics, psychiatry, preventive medicine, OB/GYN, and more. ABPM requires only current primary-specialty certification through an ABMS member board (or AOA/RCPSC/CFPC). Fellowship is 1 clinical year (a few programs add a research year).12
  • Addiction Psychiatry (ADP), the psychiatry-only route. Board: the American Board of Psychiatry and Neurology (ABPN). You must complete a full ACGME psychiatry residency (4 yrs) first, then a 1-year fellowship (PGY-5; part-time up to 2 yrs). AAAP frames ADP as the psychiatry-identity path, weighted toward co-occurring mental illness and SUD. Some physicians hold both credentials.13

Path (ADM): MD/DO (4 yrs) → any ACGME/AOA residency (typically 3–4 yrs) → 1-yr ACGME Addiction Medicine fellowship → ABPM subspecialty certification.2

  • The practice pathway has closed. Physicians could once certify without a fellowship by documenting hours of addiction practice, but that practice pathway was available only through 2025. After 2025, the ACGME fellowship is the route to ABPM certification.4 ⟳
  • Program counts (ACGME 2024–25): ~108 Addiction Medicine programs and ~54 Addiction Psychiatry programs. Addiction medicine is a young field, recognized as an ABMS subspecialty only in 2016, so a sizeable share of programs are still on initial accreditation.5
  • Total from the start of college: ~12 years for the ADM route (4 undergrad + 4 med school + 3–4 base residency + 1 fellowship). The exact number depends entirely on which base residency you come through.

How competitive is it?

The honest read: addiction medicine is genuinely accessible right now, and positions routinely go unfilled. This is the opposite of the ultra-competitive-match anxiety premeds hear about elsewhere.

  • 2026 NRMP fill (Specialties Matching Service): Addiction Medicine filled 173 of 271 positions (63.8%) across 106 programs, with 201 applicants; Addiction Psychiatry filled 77 of 112 (68.8%) across 47 programs, with 87 applicants.6 ⟳
  • Neither is a one-year fluke. Across the four cycles from 2023 to 2026, addiction medicine has filled between 59.5% and 70.1% of its positions and addiction psychiatry between 50.8% and 68.8%, so roughly one in three goes unfilled through the match in a typical year, which is applicant-friendly by any standard.6
  • Match numbers understate true capacity. Many Addiction Medicine positions are still filled outside the match, via direct/rolling application, so the real number of training slots exceeds the match table.67 ⟳
  • Competitiveness varies sharply by program. Research-heavy and brand-name programs are competitive; many community programs struggle to fill. There's a spot for a motivated applicant.

The context that explains all of this: a deep workforce shortage (below) meets an ongoing overdose crisis, and the training pipeline hasn't caught up. This is a field people tend to find rather than gun for from day one, which is exactly why it stays reachable.

Compensation — the robust version

Addiction medicine is a cognitive, largely outpatient, non-procedural field, so total comp sits in the moderate band, solidly above the all-specialty median but well below procedural specialties. A note on sources first: no single large-n survey isolates "addiction medicine" cleanly, so the best practice is to triangulate the base-specialty benchmark (psychiatry vs. FM/IM) with addiction-specific figures. The most defensible single number is the physician-verified SalaryDr median of ~$315,000, though its sample is small (n=16).8

National number. A mid-career addiction medicine physician earns roughly $300,000–$340,000 total compensation. SalaryDr (panel dated March 2025, physician-verified; read August 2026) reports median $315,000 / average $327,188 (base ~$265,625, ~81% of total; avg bonus ~$61,563). Marit's own self-reported panel splits the routes: ~$304k for the FM route vs. ~$313k for the psychiatrist route. Treat Glassdoor's model-estimated $415,616 (n=20) as skewed high, and ignore Salary.com's outdated 2021 figure entirely.89 ⟳

The spread (SalaryDr's panel of 16 physicians, directional, verify tails): 10th pct $265,000 · 25th $285,000 · median $315,000 · 75th $340,000 · 90th pct ~$500,000. Note the long right tail. The jump from 75th to 90th reflects clinicians who stack income levers rather than doing pure salaried clinical work.8 ⟳

Which route you took barely moves the number; the base specialty benchmark does. Addiction psychiatrists tend to out-earn multi-route addiction medicine physicians by a small margin (single-digit to low-double-digit thousands), and that gap comes from psychiatry itself paying a bit more than FM/IM rather than from the addiction credential. Psychiatry benchmarks: $341,977 in Doximity's 2025 report on 2024 earnings, $331,000 in Medscape's 2026 report on 2025 earnings. Both are means.910 ⟳

Experience matters more than in most fields' headline. SalaryDr's curve runs ~$282k at 3–5 years (n=6) to ~$319k at 6–10 (n=5) and ~$395k at 11–15 (n=3). Its two endpoints, ~$265k at 0–2 years and ~$500k at 16+, each rest on a single submission, so read the middle of the curve and treat the tails as one physician's report. Much of the top-end growth is income levers rather than automatic seniority pay.8 ⟳

Setting.

  • Academic: typically the lowest clinical pay, offset by protected time, teaching, research, and stability, often at the low end of the $300k band.8
  • Private practice / cash-pay: the highest ceiling. Owners of buprenorphine/MAT or cash-pay/telehealth clinics can materially exceed the upper percentiles via panel size and low overhead, which drives the $500k 90th percentile.8
  • Treatment centers (residential/IOP/OTP): mid-range salaried clinical roles, but the medical directorship is the lever that pushes comp up.8

Geography is two-sided. High-cost coastal metros pay high nominal salaries (SalaryDr's location widget, which draws on a much larger and undocumented set of reports than the 16-physician verified panel above: NYC ~$400k, LA ~$380k, Boston ~$370k, Miami ~$360k, Chicago ~$350k, Houston ~$340k), and rural/underserved markets pay premiums to attract scarce clinicians, often with loan-repayment and grant sweeteners layered on top. Barton's 2026 guide names North Dakota, Indiana, Minnesota, and Mountain West markets as consistently top-paying for psychiatry/addiction.811 ⟳

Income levers (why the ceiling is so far above the median).

  1. MAT and buprenorphine clinics, with high-throughput outpatient panels. Since the 2023 removal of the DEA X-waiver, any DEA-registered prescriber can prescribe buprenorphine, widening who can build these panels.12
  2. Cash-pay and telehealth models, with abundant remote buprenorphine and SUD roles, many of them part-time or hourly. Cash-pay lifts the effective hourly rate by dodging insurance overhead. No survey prices this segment, so treat it as a structural feature of the field rather than a number.13
  3. Medical directorships of treatment centers, whose stipends stack on clinical income; a common route to the $400k+ tier.8
  4. Locum tenens, where psychiatry/addiction rates run ~$225–$235/hour (Barton 2026), well above the ~$129/hr W-2-equivalent for employed psychiatry.11

The trend that colors all of it. Demand is structurally strong. A deep workforce shortage (below) meets an ongoing overdose crisis and sustained federal, state, and opioid-settlement funding, much of it targeting the underserved areas that also carry pay premiums. The cross-current: the base clinical salary here is set by general psychiatry and FM/IM rather than by the addiction credential, so the upside comes from the income levers above.1014 ⟳

Lifestyle & the trade at the heart of the field

The most-cited pro of addiction medicine: it's one of the more livable schedules in medicine, and that's structural, not luck. The work is largely outpatient, most settings involve little to no overnight call, and much of it is telehealth-compatible (post-2020 rule changes made buprenorphine induction and maintenance heavily virtual-friendly). Physicians self-report roughly a 42-hour work week with high schedule control, and part-time or hybrid arrangements, addiction work bolted onto a base specialty, are common and easy to build.15

The most-cited con is the patients you carry. Addiction is a chronic, relapsing disease, and the overdose crisis is the backdrop of the whole specialty. Some patients you know well will relapse, disappear, overdose, or die. The demanding part of this field is emotional and systemic, not logistical (see Wellbeing).

Lifestyle rating: 4/5. Genuinely high schedule control, minimal call, and remote-workable, with the honest asterisk that the emotional load is heavy even when the calendar is light.

Wellbeing — the part to take seriously

Burnout here is real but variable and sourced differently than in high-acuity fields. It rarely comes from hours or call. It comes from three things, and they deserve to be named plainly:

  • The emotional load of relapse and mortality. With tens of thousands of US overdose deaths a year, loss is structural to the work rather than an occasional event. You keep showing up for people the disease keeps pulling back.
  • Stigma against the field itself. Addiction medicine is stigmatized inside medicine, not just outside it: colleagues who view the patients as less deserving, or the specialty as lower-status. That secondhand contempt is a documented burnout driver.16
  • A system that undervalues the work. Reimbursement, staffing, and political support for MAT and harm reduction are precarious and swing with the political winds. Qualitative research on hospital-based addiction providers ties burnout specifically to systemic under-resourcing and stigma rather than to the patients themselves.17

The other side is also real, and unusually strong. People in this field consistently describe some of the most concretely life-saving work in medicine. Buprenorphine genuinely pulls people back from death, and you see it. That sense of purpose is a major protective factor. Self-reported satisfaction runs high, around 4.1/5, with "would choose it again" at strikingly high rates (small-sample self-report, but consistent with how insiders talk).8 And the controllable, combinable schedule makes it a field people sustain for decades, or step into mid-career as a lower-intensity pivot from a harder specialty.15

Honest framing: the people who thrive here are the ones for whom the meaning outweighs the loss, and many genuinely find that it does.

Who's in the field (demographics)

Sex is published for the fellows; race and the practicing workforce are not. ACGME's Data Resource Book AY2024-25, Table C.21, gives addiction medicine (multidisciplinary) 108 programs and 216 fellows, 114 of them women (52.8%) and 98 men (45.4%), with 4 unreported (1.9%). The sibling addiction psychiatry fellowship runs 54 programs and 79 fellows, 40.5% women. Both are trainee counts on small rows rather than workforce figures, so read them as that. For practicing physicians no current by-specialty race table is published at all; the last citable one is AAMC's Diversity in Medicine (2019). AAMC's workforce dashboard leaves out any specialty under 2,500 active physicians, which covers both of these fields, so no %-women, %DO or %IMG figure exists for either practicing workforce.18 ⟳

What can be said:

  • Workforce is tiny relative to need. Fewer than ~2,500 certified addiction medicine physicians and ~2,000 addiction psychiatrists (~4,500 total) by one count; a broader count puts board-certified addiction medicine physicians at under ~7,000, against the ~48.5 million Americans aged 12 and over who met criteria for a substance use disorder in 2023. For scale, ~22,500 cardiologists practice in the US (~5x the addiction workforce).1419 ⟳
  • The entering cohort is documented, and it does not skew IMG- or DO-heavy. ACGME's Table C.15 puts addiction medicine's 216 fellows at 61.6% US LCME graduates, 20.8% IMG and 17.6% osteopathic in AY2024-25. NRMP's 2026 match fills the same picture in: of 173 filled positions, 59.0% went to US MD graduates, 18.5% to US DO graduates, 15.0% to US IMGs and 7.5% to non-US IMGs. Both sit at or just below the all-GME shares in the context line below, so the open base-specialty eligibility that makes this fellowship easy to reach does not produce an entering class tilted toward IMGs or DOs.186 ⟳
  • Context (all-GME, NOT ADM/ADP-specific): among ACGME core-specialty trainees in 2024–25, ~57.8% US MD, ~22.5% IMG, ~19.6% US DO. Applying these to addiction subspecialties specifically would be an assumption.18

(Per site policy, we do not report a per-specialty first-generation statistic, because no reliable data exists, but the FLI angle below is the point of this whole site.)

Culture, personality & the online stereotypes

Kind realism: the patterns below are the field's online and community reputation, not gospel. Plenty of people don't fit them, and this is a population and a field that have both been badly served by lazy characterization, so read them as attributed perception, not verdict.

Who gravitates here: the reputation is that addiction medicine draws mission-driven, non-judgmental, social-justice-minded physicians, people who find meaning caring for a stigmatized, underserved population much of the rest of medicine would rather avoid. The read online is that it selects for people comfortable with chronic, relapsing disease and slow, partial wins ("slow medicine," meaning relationship-building over months, closer to managing diabetes than curing pneumonia), who don't need the ego reward of a dramatic save, and who can hold hope for a patient the system has written off. Harm reduction, meeting patients where they are rather than demanding abstinence, sits near the cultural center of gravity. It's also described as a notably welcoming, less status-obsessed corner of medicine, with far less of the ego-jockeying of more prestigious fields.20

The stereotypes. community caricatures, not facts. Each with a humanizing counterpoint:

  • "The lowest-status specialty." Reframed honestly: the low status reflects stigma against the patients rather than the difficulty or value of the work, and the field exists precisely to counter that bias.
  • "You're just a legal drug dealer." A cruel online jab at buprenorphine prescribing. Reality: medication-assisted treatment is among the best-evidenced, most life-saving interventions in medicine; the caricature is exactly the misconception the field fights.
  • "Nothing works / it's hopeless because everyone relapses." Reframes a chronic, relapsing disease as a personal failing. Relapse is part of the disease course, and partial wins genuinely save lives. The "slow medicine" mindset is the expertise rather than a consolation prize.
  • "A soft, easy lifestyle field." True that the schedule is livable, but the framing misses that the difficulty here is emotional and systemic rather than a lack of rigor.

What people say online (synthesized and paraphrased from public discussion, not quoted): the picture is strikingly consistent and two-sided. People describe some of the most rewarding work in medicine and are unusually vocal that they'd choose it again, and the "you actually save lives and see it" sentiment recurs. The lifestyle is praised as a top reason people add it to a base specialty: controllable hours, minimal call, telehealth, easy part-time. The stigma complaint is constant, with frustration at colleagues who look down on the patients or the field, and at a system that funds MAT and harm reduction grudgingly. The emotional toll is named honestly, with patient deaths and relapse as the real cost, plus regulatory friction around controlled-substance prescribing. And it's widely flagged as accessible and underfilled, a one-year fellowship reachable from many specialties, often recommended to people who want meaning and balance over maximum pay.

Voices from the field. Paraphrased from public writing, with links to the originals:

  • Taylor Moss, MPH & Devika Bhushan, MD, argue that stigma and "medical gaslighting" around addiction actively cost lives, with fewer than 1 in 5 of the ~48 million Americans with a SUD getting treatment, and that addiction specialists are the clinicians most likely to treat it as the disease it is.21
  • Dr. Megana Dwarakanath, an adolescent-medicine fellow, frames harm reduction as being as fundamental as "do no harm," recounts an attending saying out loud "You wouldn't want your kid next to a drug addict" about a teenager seeking care, and captures the emotional core of the work in a patient who, for the first time, was "not feeling ashamed."16
  • Serowik and colleagues, studying hospital-based addiction providers, find burnout driven by systemic under-resourcing and stigma while meaning, purpose, and team support build resilience. The toll is structural rather than from the patients.17
  • Workforce researchers repeatedly call addiction medicine "one of medicine's best-kept secrets," a genuine growth area people tend to find by accident rather than by design, and a big reason the shortage persists despite booming demand.22

Why people choose it / why people leave

Why choose it: genuinely life-saving, high-meaning work where you see the impact directly · controllable lifestyle, with predictable hours, minimal call, telehealth, and part-time and hybrid options · accessible entry via a one-year fellowship reachable from almost any base specialty · strong, durable, crisis-driven demand in a growth field · combinable with your base specialty · loan-repayment-eligible roles common · a welcoming, less status-obsessed culture.

Why leave or avoid it: the emotional load of relapse and death is real and recurring · stigma from colleagues and society attaches to the field and its patients · systemic headwinds including grudging funding, regulatory friction, and political volatility around MAT/harm reduction · moderate pay relative to procedural specialties · you're often swimming against a system that undervalues work you know saves lives.

Best fit if: you find meaning in caring for people the rest of medicine overlooks and don't need prestige or a dramatic save to feel it was worth it · you're comfortable with chronic, relapsing disease and slow, partial wins · you want real work-life balance and schedule control without leaving direct patient care · harm reduction and meeting people where they are resonate with you.

Not for you if: recurring patient loss and relapse would be emotionally unsustainable · you need high status, high pay, or unambiguous cures to feel satisfied · you'd resent working inside an under-resourced, politically contested part of the system · you prefer acute, procedure-heavy, fast-resolution medicine.

The FLI angle — Addiction Medicine for first-gen, low-income & immigrant students

If you're first-gen, low-income, or immigrant, addiction medicine is worth a serious look, practically and not just idealistically.

Where it fits FLI realities well:

  • The entry is unusually reachable, and low-risk. It's a single-year fellowship you can enter from almost any base specialty. You don't have to gamble years on an ultra-competitive match to get here: you can become a fully practicing, fully earning physician first in a broad field like family or internal medicine, then add addiction training after. That lower-risk, lower-cost path matters more when there's no financial cushion behind you.
  • The demand is real and funded. The overdose crisis has created durable, crisis-driven demand and dedicated funding: federal and state grants, opioid-settlement dollars, and loan-repayment programs (NHSC and similar), with jobs in community health, VA, and public-health settings. Many roles are loan-repayment eligible, a concrete lever against six-figure medical debt.
  • The mission fits. This is work rooted in underserved communities, often the same communities FLI students come from. If part of why you want to be a doctor is to serve people the system overlooks, few fields let you do that as directly.

Risks to name honestly:

  • The pay is moderate, not top-tier. This is a "comfortable and meaningful," not "maximum-earning," path. If you're the family breadwinner, that math deserves an honest look. The income levers (cash-pay/telehealth clinics, directorships) can raise the ceiling, but the median is squarely mid-band.
  • The stigma and emotional load are genuine. The field asks you to keep showing up for patients who relapse, inside a system that undervalues the work. That is a reason to walk in with your eyes open rather than a reason to avoid the field.

Bottom line: addiction medicine is one of the most reachable, most mission-aligned routes in all of medicine: a one-year fellowship from almost any base, aimed at a crisis with real funding behind it, serving communities many FLI students come from. The trade is moderate (not maximum) pay and a genuine emotional and systemic load. Hope for the loan-repayment path; plan for the debt either way. And know that if meaning is the thing that gets you out of bed, this is one of the fields where it's easiest to find.

Subspecialties, related paths & the two roads in

Addiction medicine is itself a subspecialty, reached after a base residency, so rather than sub-subspecialties, the key branches are the routes in and the settings you can build a career around.

  • Addiction Medicine (ABPM). The multidisciplinary credential, open from nearly any base specialty (IM, FM, EM, Peds, Prev Med, OB/GYN, and more). The widest front door.12
  • Addiction Psychiatry (ABPN). The psychiatry-only credential, weighted toward co-occurring mental illness and SUD. Some physicians hold both.13
  • Practice settings that function like career flavors: office-based MAT / buprenorphine clinics · hospital addiction consult services · opioid treatment programs (OTPs) / methadone · residential and intensive-outpatient (IOP) programs · telehealth/cash-pay models · VA, correctional, and public-health roles · treatment-center medical directorship (an administrative + income lever) · academic addiction medicine (teaching, research, protected time).

Fun facts

  • Addiction medicine became an ABMS-recognized subspecialty only in 2016 (sponsored by the American Board of Preventive Medicine), despite addiction being one of the oldest problems in medicine.1
  • The widest front door in medicine. It's one of very few subspecialties open to physicians from nearly every primary specialty.12
  • Two roads in. Addiction medicine (ABPM, from any base) and addiction psychiatry (ABPN, a psychiatry subspecialty) are distinct but overlapping paths to similar work.13
  • Much of the field's daily impact runs through one drug, buprenorphine, and the 2023 removal of the "X-waiver" made it far easier for any DEA-registered prescriber to offer it.12
  • Workforce researchers repeatedly call this "medicine's best-kept secret," noting most people find it by accident rather than by plan, a big reason the specialist shortage persists despite booming demand.22
  • The practice pathway just closed. After 2025, the fellowship is the only route to ABPM certification, and the field is formalizing as it grows.4

Sources

Footnotes

  1. The two distinct credentials (ADM/ABPM, multidisciplinary; ADP/ABPN, psychiatry-only), ABMS recognition of addiction medicine in 2016, entry requirements, and fellowship lengths. ABMS newsroom, "ABMS Officially Recognizes Addiction Medicine as a Subspecialty" (2016) (https://www.abms.org/newsroom/abms-officially-recognizes-addiction-medicine-as-a-subspecialty/); AAAP fellowship resources (2025/26) (https://www.aaap.org/fellowship/); ABPM Addiction Medicine overview (https://www.theabpm.org/become-certified/subspecialties/addiction-medicine/). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  2. ADM training path and open base-specialty eligibility (any ABMS/AOA/RCPSC/CFPC primary certification). ABPM Addiction Medicine — Fellowship Pathway (2025/26) (https://support.theabpm.org/hc/en-us/articles/27747855703579-Addiction-Medicine-Certification-Fellowship-Pathway); The EMRA Fellowship Guide, previously cited here, has been retired and its pages no longer resolve; the ABPM fellowship-pathway page above carries the training requirements. ↩ ↩2 ↩3 ↩4

  3. ADP training path (psychiatry residency → 1-yr fellowship, PGY-5; part-time up to 2 yrs). AAAP fellowship resources (https://www.aaap.org/fellowship/); ACGME Addiction Psychiatry FAQs (12/2025) (https://www.acgme.org/globalassets/pdfs/faq/401_addictionpsychiatry_faqs.pdf). ↩ ↩2 ↩3

  4. The practice ("experiential") pathway closed on the ABPM side, and the ACGME fellowship is the route there now. The AOA route is separate and has its own timing, which matters if you are a DO: ACAAM records the AOA clinical practice pathway as open until 2026, after which an AOA- or ACGME-accredited fellowship is required. ACAAM, Certification for Addiction Medicine Specialists (https://www.acaam.org/certification-for-addiction-medicine-specialists); ACMT Board Certification in Addiction Medicine Resources (https://www.acmt.net/admedcert/). ABPM's own practice-pathway article now sits behind a sign-in, so it is not linked here. ⟳ Verify — both boards restate these dates annually. ↩ ↩2

  5. Program counts (ACGME 2024–25): ~108 Addiction Medicine, ~54 Addiction Psychiatry; accreditation-status split. ACGME Data Resource Book 2024–2025 (https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf); ACAAM (https://www.acaam.org/index.php?option=com_dailyplanetblog&tag=fellowship-programs). ↩

  6. NRMP Specialties Matching Service, 2026 appointment year, Tables 1A and 2 (ADM 271 offered, 173 filled, 63.8%, 201 applicants, 106 programs; ADP 112 offered, 77 filled, 68.8%, 87 applicants, 47 programs), and the note that many ADM slots fill outside the match. NRMP SMS Results and Data, February 2026 (https://www.nrmp.org/wp-content/uploads/2026/02/SMS_Results_and_Data_Report2026.pdf). ↩ ↩2 ↩3 ↩4

  7. ADM historically described as apply-direct/rolling, so match numbers understate capacity. Previously cited to the EMRA Fellowship Guide, which has been retired and no longer resolves. The claim is left in place as a characterization of how the fellowship has been described rather than a counted figure; ABPM's fellowship-pathway page (see 2) is the live authority on requirements, and it does not publish application mechanics. ⟳ ↩

  8. Addiction-medicine-specific compensation — median/average total comp, percentile spread (long right tail to ~$500k 90th pct), experience curve, city averages, satisfaction ~4.1/5, ~42-hr week, and academic/private/treatment-center directional benchmarks. SalaryDr Addiction Medicine (physician-verified, n=16 — small sample, verify) (https://www.salarydr.com/specialty/addiction-medicine). Corrected 2026-08-17: this page dated the panel July 2026, which is a crawl date rather than a data date. The page itself carries three: "Data updated March 2025 | 16 verified submissions", an as-of date of March 26 2025 on the $315,000 figure, and a "Last updated" stamp of August 17 2026. Every figure quoted here is verbatim from the page; only the vintage was wrong, and the panel is now dated March 2025 with the access date separate. The same correction is applied to the experience curve, whose per-bucket sample sizes the page publishes and this profile did not: 0–2 yrs $265,000 (n=1) · 3–5 $281,667 (n=6) · 6–10 $319,000 (n=5) · 11–15 $395,000 (n=3) · 16+ $500,000 (n=1). The two endpoints each rest on one submission, and the $500,000 at 16+ years is the same datum as the 90th percentile. The city averages are a separate SalaryDr location widget reporting 70–150 "reports" per city against a 16-physician national panel; they are labeled as such rather than presented as part of it. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10

  9. Route split (~$304k FM route vs. ~$313k psychiatrist route, from Marit's own self-reported panel rather than the masked MGMA benchmark) and cautions on model-estimated/outdated aggregators. Marit Health (2026) (https://www.marithealth.com/o/-/addiction-medicine-physician-family-medicine/salary and https://www.marithealth.com/o/-/addiction-medicine-psychiatrist/salary); Glassdoor (2026) (https://www.glassdoor.com/Salaries/addiction-medicine-physician-salary-SRCH_KO0,28.htm); Salary.com (2021, outdated) (https://www.salary.com/research/salary/posting/addiction-medicine-physician-salary). On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. On Salary.com: its CompAnalyst benchmark is HR-reported employer survey data blended with job-posting data, not a physician panel. It is base-weighted and so runs low against total-compensation surveys, and it is used here for percentile structure rather than for levels. ↩ ↩2

  10. Psychiatry base benchmark (the driver of the ADM-vs-ADP gap): $341,977 in Doximity's 2025 report on 2024 earnings (~37,000 US physicians), $331,000 in Medscape's 2026 report on 2025 earnings. Both publish means rather than medians, and neither is inflation-adjusted. Doximity 2025 Physician Compensation Report (https://www.doximity.com/reports/physician-compensation-report/2025); Medscape Psychiatrist Compensation Report 2026 (https://www.medscape.com/p11/medscape-psychiatrist-compensation-report-2026-evaluating-2026a1000e9a). Corrected 2026-08-17: this page called Doximity's $341,977 a median and described Medscape as moving from ~$341k in 2025 to ~$331k in 2026, a ~3% dip that then carried the compensation section's closing argument. Both halves are wrong. Doximity publishes a mean, and the earlier-edition Medscape figure has no verified source, so the year-over-year direction is dropped rather than reversed — the same correction the sibling addiction-psychiatry profile made in its 8 on 2026-08-13. ↩ ↩2

  11. Geography (rural/underserved premiums, top-paying states) and locum rates ($225–235/hr) vs. employed equivalent; psychiatry signing bonuses ($38,215, 2025). Barton Associates Psychiatrist Salary Guide (2026) (https://www.bartonassociates.com/psychiatrist-salary-guide/). ↩ ↩2

  12. 2023 removal of the DEA X-waiver requirement, broadening buprenorphine prescribing. Covered in the compensation and lifestyle research syntheses (SalaryDr / ASAM context); see ASAM Certification Pathways (https://www.asam.org/education/addiction-medicine-certification/certification-pathways-new). Corrected 2026-08-17: this footnote carried a caveat about SalaryDr's undisclosed panel size, which had nothing to caveat — the footnote cites no SalaryDr page and quotes no figure, and where SalaryDr is genuinely the source, at 8 and 15, the panel size is published and disclosed as n=16. ↩ ↩2

  13. Removed 2026-08-13. This footnote carried a $109k–$250k range for remote buprenorphine roles from ZipRecruiter job postings. Job-board postings are not a compensation survey — they have no panel and no sample size, so there is nothing to caveat — and no survey prices the remote and cash-pay MAT segment separately. The structural claim stands without a number. ↩

  14. Workforce shortage and demand tailwinds — fewer than ~2,500 addiction medicine physicians and ~2,000 addiction psychiatrists (~4,500 total); access gap (~18% of adults with OUD receive medication; ~60% of rural Americans in a county with no buprenorphine-waivered provider); federal/SAMHSA/HRSA/settlement funding. Psychiatric Services (2020–21) (https://psychiatryonline.org/doi/10.1176/appi.ps.202000565); ASAM training brief (https://www.asam.org/docs/default-source/advocacy/asam-training-demo-one-pagerb1ff289472bc604ca5b7ff000030b21a.pdf); HRSA State of the Behavioral Health Workforce 2025 (https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/data-research/Behavioral-Health-Workforce-Brief-2025.pdf). ↩ ↩2

  15. Lifestyle — largely outpatient, minimal overnight call, telehealth-friendly, ~42-hr self-reported week with high schedule control, part-time/combinable models, and career longevity. SalaryDr Addiction Medicine (panel dated March 2025, read August 2026) (https://www.salarydr.com/specialty/addiction-medicine). SalaryDr panel size: n=16. A self-selected physician panel; the n is disclosed here because it is what the figure rests on. ↩ ↩2 ↩3

  16. Stigma against the field/patients as a burnout driver, and the emotional core of the work. Megana Dwarakanath, MD — Doximity Op-Med, "Harm Reduction Is as Useful as 'Do No Harm'" (https://opmed.doximity.com/articles/harm-reduction-is-as-useful-as-do-not-harm). ↩ ↩2

  17. Burnout among hospital-based addiction providers driven by systemic under-resourcing and stigma, not the patients; meaning and team support build resilience. Serowik et al., Journal of Substance Abuse Treatment, 2022 (https://www.sciencedirect.com/science/article/abs/pii/S0740547222002069). ↩ ↩2

  18. Fellow sex, the remaining demographic gaps, and all-GME context. ACGME Data Resource Book, Academic Year 2024-2025, Table C.21 — addiction medicine (multidisciplinary): 108 programs, 216 fellows, 114 women (52.8%), 98 men (45.4%), 4 not reported (1.9%); addiction psychiatry: 54 programs, 79 fellows, 32 women (40.5%), 47 men (59.5%), 0 not reported. No URiM breakdown for either fellowship, and no race table for the practicing workforce. Corrected 2026-08-17: this footnote said C.21 carries no %DO or %IMG breakdown, and the page turned that into a bullet inferring, "plausible (not documented)", that ADM entrants skew more IMG- and DO-friendly than closed surgical subspecialties. The breakdown is published, in a different table, and it points the other way. Table C.15 (Active Residents by Specialty and Subspecialty and Medical School Type) gives addiction medicine (multidisciplinary) 216 fellows: 133 US LCME (61.6%), 45 international medical school (20.8%), 38 osteopathic (17.6%), against the book's own TOTAL PIPELINE row of 57.7% / 22.7% / 19.6%. NRMP SMS 2026 Table 2 agrees: of 173 filled positions, 102 US MD (59.0%), 32 US DO (18.5%), 26 US IMG (15.0%), 13 non-US IMG (7.5%), 0 Canadian. Both instruments put the field at or slightly below the all-GME shares on both axes, so the inference has been replaced by the two published rows. All-GME context (2024–25: ~57.8% US MD, ~22.5% IMG, ~19.6% US DO) is not addiction-specific. Corrected 2026-08-17: this page said the subspecialty breakdowns were not cleanly published and that C.21 gives head counts rather than percentages on rows small enough that the unknown share moves them. C.21 prints both, and the unreported share is 4 of 216 for addiction medicine and 0 of 79 for addiction psychiatry, which moves neither. Both percentages are now stated, the quick dashboard's % women / demographics row with them, and the gap language is kept for race and for the practicing workforce. ACGME 2024–25 statistics release, Jan 2026 (https://www.acgme.org/newsroom/2026/1/acgme-releases-2024-2025-statistics-on-graduate-medical-education-programs-and-resident-physicians/); ACGME Data Resource Book 2024–2025 (https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf); AAMC Report on Residents Table B3 (https://www.aamc.org/data-reports/students-residents/data/report-residents/2024/table-b3-number-active-residents-type-medical-school-gme-specialty-and-gender). ↩ ↩2 ↩3

  19. Broader workforce count — "fewer than 7,000 board-certified addiction medicine physicians"; AAMC shortage projection. ACAAM Addiction Medicine Fellowship Program Directors' Guide, Oct 2025 (https://www.acaam.org/assets/docs/Fellowship/ADM%20FD%20Guide_Final_10.15.2025.pdf). The denominator is SAMHSA's own: 48.5 million people aged 12 or older, 17.1% of that population, met criteria for a past-year substance use disorder in 2023 — Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (https://www.samhsa.gov/data/sites/default/files/reports/rpt47095/National%20Report/National%20Report/2023-nsduh-annual-national.htm). Corrected 2026-08-17: this page carried two denominators for one fact, the ACAAM guide's "46+ million" here and "~48 million" in the Voices section, each attributed to a different source. Both are readings of NSDUH at different vintages; the page now states the survey's own current figure once, and the Voices paraphrase keeps the number its authors used. ⟳ ↩

  20. Culture / who-gravitates (mission-driven, non-judgmental, harm-reduction-centered, less status-obsessed; comfortable with chronic relapsing disease and slow wins). Synthesized from field lifestyle/culture research and physician forums (r/medicine, r/psychiatry, r/FamilyMedicine, SDN — paraphrased, not quoted). ↩

  21. Stigma and "medical gaslighting" as lethal; fewer than 1 in 5 of ~48M Americans with SUD get treatment. Taylor Moss, MPH & Devika Bhushan, MD — KevinMD, 2026 (https://kevinmd.com/2026/07/how-addiction-stigma-in-health-care-costs-lives.html). ↩

  22. "One of medicine's best-kept secrets" — people find the field by accident, sustaining the shortage. EurekAlert!/BMC Medical Education, 2026 (https://www.eurekalert.org/news-releases/1130630). ↩ ↩2

Researched with AI assistance and reviewed by hand. How this site is made